Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

被引:128
作者
Bejon, P
Andrews, L
Andersen, RF
Dunachie, S
Webster, D
Walther, M
Gilbert, SC
Peto, T
Hill, AVS
机构
[1] Univ Oxford, Churchill Hosp, Wellcome Ctr Human Genet, Oxford OX3 7LJ, England
[2] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England
基金
英国医学研究理事会;
关键词
D O I
10.1086/427243
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We calculated the number and growth rate of Plasmodium falciparum parasites emerging in recipients of candidate preerythrocytic malaria vaccines and unvaccinated control subjects undergoing mosquito-bite challenge. This was done to measure vaccine efficacy and to distinguish the effects on blood-stage multiplication from those on liver-stage parasites. Real-time polymerase chain reaction measurements of parasite densities were analyzed by nonlinear regression and mixed-effects models. Substantial reductions in numbers of liver parasites resulted from the use of 2 immunization regimens: FP9 boosted by modified virus Ankara (MVA) encoding the malaria epitope-thrombospondin-related adhesion protein insert (92% reduction) and RTS, S/AS02 used in heterologous prime-boost immunization regimens, with MVA encoding the circumsporozoite protein (97% reduction). Forty-eight-hour growth rates in blood from control subjects were not different from those in blood from any vaccination group (mean, 14.4-fold [95% confidence interval, 11-19- fold]).
引用
收藏
页码:619 / 626
页数:8
相关论文
共 18 条
[1]  
BEIER JC, 1992, J AM MOSQUITO CONTR, V8, P404
[2]   A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts [J].
Birkett, A ;
Lyons, K ;
Schmidt, A ;
Boyd, D ;
Oliveira, GA ;
Siddique, A ;
Nussenzweig, R ;
Calvo-Calle, JM ;
Nardin, E .
INFECTION AND IMMUNITY, 2002, 70 (12) :6860-6870
[3]  
Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO
[4]  
2-Z
[5]   Measurement of Plasmodium falciparum growth rates in vivo: A test of malaria vaccines [J].
Cheng, Q ;
Lawrence, G ;
Reed, C ;
Stowers, A ;
RanfordCartwright, L ;
Creasey, A ;
Carter, R ;
Saul, A .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 57 (04) :495-500
[6]   Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved preerythrocytic liver-stage antigen 3 [J].
Daubersies, P ;
Thomas, AW ;
Millet, P ;
Brahimi, K ;
Langermans, JAM ;
Ollomo, B ;
Ben Mohamed, L ;
Slierendregt, B ;
Eling, W ;
Van Belkum, A ;
Dubreuil, G ;
Meis, JFGM ;
Guérin-Marchand, C ;
Cayphas, S ;
Cohen, J ;
Gras-Masse, H ;
Druilhe, P .
NATURE MEDICINE, 2000, 6 (11) :1258-1263
[7]   Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR [J].
Hermsen, CC ;
Telgt, DSC ;
Linders, EHP ;
van de Locht, LATF ;
Eling, WMC ;
Mensink, EJBM ;
Sauerwein, RW .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2001, 118 (02) :247-251
[8]  
HERRINGTON DA, 1988, TROP GEOGR MED, V40, P124
[9]   Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans [J].
McConkey, SJ ;
Reece, WHH ;
Moorthy, VS ;
Webster, D ;
Dunachie, S ;
Butcher, G ;
Vuola, JM ;
Blanchard, TJ ;
Gothard, P ;
Watkins, K ;
Hannan, CM ;
Everaere, S ;
Brown, K ;
Kester, KE ;
Cummings, J ;
Williams, J ;
Heppner, DG ;
Pathan, A ;
Flanagan, K ;
Arulanantham, N ;
Roberts, MTM ;
Roy, M ;
Smith, GL ;
Schneider, J ;
Peto, T ;
Sinden, RE ;
Gilbert, SC ;
Hill, AVS .
NATURE MEDICINE, 2003, 9 (06) :729-735
[10]   FINE-STRUCTURE OF PLASMODIUM-BERGHEI EXOERYTHROCYTIC FORMS IN CULTURED PRIMARY RAT HEPATOCYTES [J].
MEIS, JFGM ;
VERHAVE, JP ;
MEUWISSEN, JHET ;
JAP, PHK ;
PRINCEN, HMG ;
YAP, SH .
CELL BIOLOGY INTERNATIONAL REPORTS, 1984, 8 (09) :755-765